

Cite this: *Mol. BioSyst.*, 2015,
11, 3279

Characterisation of SEQ0694 (PrsA/PrtM) of *Streptococcus equi* as a functional peptidyl-prolyl isomerase affecting multiple secreted protein substrates†

Felicia Ikolo,^{ab} Meng Zhang,^a Dean J. Harrington,^c Carl Robinson,^d
Andrew S. Waller,^d Iain C. Sutcliffe*^a and Gary W. Black^a

Peptidyl-prolyl isomerase (PPIase) lipoproteins have been shown to influence the virulence of a number of Gram-positive bacterial human and animal pathogens, most likely through facilitating the folding of cell envelope and secreted virulence factors. Here, we used a proteomic approach to demonstrate that the *Streptococcus equi* PPIase SEQ0694 alters the production of multiple secreted proteins, including at least two putative virulence factors (FNE and IdeE2). We demonstrate also that, despite some unusual sequence features, recombinant SEQ0694 and its central parvulin domain are functional PPIases. These data add to our knowledge of the mechanisms by which lipoprotein PPIases contribute to the virulence of streptococcal pathogens.

Received 12th August 2015,
Accepted 8th October 2015

DOI: 10.1039/c5mb00543d

www.rsc.org/molecularbiosystems

Introduction

In order to interact with their environments, bacteria translocate significant numbers of proteins across their plasma membranes, either for eventual release (secretion) or for localisation within the cell envelope.^{1–3} In pathogens, this ‘secretome’ plays a vital role in host–pathogen interactions and consequently the mechanisms of protein translocation are of much interest as ‘virulence-associated’ functions. Proteins exported by the Sec translocase emerge on the extracytoplasmic side of the plasma membrane as unfolded proteins and the subsequent correct folding of these proteins is therefore critical to their functioning. In ‘diderm’ bacteria (those with outer membranes), a variety of periplasmic chaperones are required to allow protein folding in the periplasm and/or translocation across or into the outer membrane.^{1,4} In monoderm Gram-positive bacteria, secreted proteins fold at the membrane-wall interface with the assistance of a range of accessory components

of the Sec translocase.⁵ These include proteins belonging to the peptidyl-prolyl Isomerase (PPIase) family, which assist protein folding by catalysing *cis*–*trans* isomerisation of the peptide bond preceding proline residues.^{6,7} In many Gram-positive bacteria, these PPIases are N-terminally lipid-anchored lipoproteins, presumably because the localisation of a PPIase peripheral to the plasma membrane surface places it in an optimal position to engage with substrate proteins emerging from the Sec translocon.⁸

Several lipoprotein PPIases have been shown to have significant roles in bacterial physiology, notably PrsA in *Bacillus subtilis*.⁹ Moreover, in some pathogens PPIases have been shown to affect virulence,⁷ including PrsA of *Bacillus anthracis*,¹⁰ *Enterococcus faecalis* EF0685 and EF1534,¹¹ *Listeria monocytogenes* PrsA2,^{12,13} *Streptococcus pneumoniae* SlrA and PpmA¹⁴ and *Streptococcus pyogenes* PrsA.¹⁵ Some of these PPIase belong to the cyclophilin subfamily (e.g. *S. pneumoniae* SlrA; *E. faecalis* EF1534) but many belong to the parvulin subfamily,¹⁶ including the members of PrsA family that appear to be ubiquitous in *Firmicute* genomes.

Streptococcus equi is the causative agent of the widespread equine disease Strangles.^{17,18} We have previously shown that the PrsA homologue of *S. equi* (UniProt: C0M9L5, originally denoted PrtM) plays a significant role in *S. equi* virulence, both in an air interface tissue culture model, a mouse model and, most significantly, in the equine host.¹⁹ PrtM is here referred to as SEQ0694, based on its annotation in the *S. equi* genome.¹⁷

To further investigate the role of SEQ0694 we have here characterised the recombinant protein as a functional PPIase and used a proteomic approach to demonstrate that SEQ0694 likely influences the folding and activity of multiple secreted

^a Department of Applied Sciences, Faculty of Health & Life Sciences, University of Northumbria at Newcastle, Newcastle upon Tyne, NE1 8ST, UK.
E-mail: iain.sutcliffe@northumbria.ac.uk; Fax: +44 (0)191 227 3519;
Tel: +44 (0)191 227 4071

^b Department of Biochemistry, School of Medicine, St. George's University, True Blue, St. George's, Grenada

^c Division of Biomedical Science, School of Life Sciences, University of Bradford, West Yorkshire, BD7 1DP, UK

^d Centre for Preventive Medicine, Animal Health Trust, Lamwades Park, Kentford, Newmarket, Suffolk CB8 7UU, UK

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5mb00543d



proteins of *S. equi*, including at least two putative virulence factors.

Materials and methods

Bacterial strains and growth

S. equi strain 4047 (wild type) and its isogenic mutant strain (Δ *prtM*_{138–213}) with a deletion of codons 138 to 213 in *seq0694* (*i.e.* lacking the central domain of SEQ0694, ESI,† Fig. S1) are described in Hamilton *et al.*¹⁹ *S. equi* strains were grown in Todd Hewitt media. *Escherichia coli* TOP10 and BL21 were grown in LB media.

Production and purification of recombinant proteins

Genomic DNA from *S. equi* 4047 was isolated using a DNeasy extraction kit (Qiagen). To produce recombinant N-terminally His-tagged full-length SEQ0694 (rSEQ0694), the *seq0694* ORF, minus the sequence encoding the signal peptide, was amplified from *S. equi* 4047 genomic DNA using the primer pair 5' GATC GATCCATATGTGTCAGTCTACAAATGACAATACAAGTG 3' (forward primer, *NdeI* site underlined) and 5' GATCGATCCTCGA GATATTTTCTGACTTAGATTTAGAAGATTGAC 3' (reverse primer, *XhoI* site underlined) and KOD Hot Start polymerase (Merck Chemicals) according to the manufacturer's instructions. The amplified ORF was cloned into pET28a (Merck Chemicals) using *NdeI-XhoI* and expressed in *E. coli* BL21(DE3) grown at 37 °C with shaking at 200 rpm, to an absorbance of 0.6 at 600 nm, in LB medium supplemented with 100 µg mL⁻¹ kanamycin. Induction was performed by the addition of isopropyl-1-thio-β-D-galactopyranoside to a concentration of 240 µg mL⁻¹, followed by further incubation for 18 h at 30 °C with shaking at 100 rpm. rSEQ0694 was purified according to the method of Malik *et al.*,²⁰ except that the purified protein was concentrated and the buffer exchanged into 18.2 MΩ cm⁻¹ water using 10 kDa cut-off centrifugal concentrator units (Viva Science). The identity of rSEQ0694 was confirmed by peptide mass fingerprinting of trypsinized bands excised from Coomassie blue-stained SDS-polyacrylamide gels (see below).

In addition to rSEQ0694, the section of the *seq0694* ORF encoding the predicted parvulin domain of SEQ0694 (amino acids 148–242, ESI,† Fig. S1; rSEQ0694parv) was amplified using primer pair TGCCATAGCATATGACTACTCAGGTCCTACTCTAG ACAATG (forward, *NdeI* site underlined) and TGCCATAGCT CGAGTTAGGCTTTTTTGGTTACCTTAACA (reverse, *XhoI* site underlined), cloned, expressed and the protein purified as described above, except that 5 kDa, 6 mL cut-off concentrator units (Viva Science) were used.

The concentration of both purified proteins was determined using the Bradford Assay.

Protease-coupled peptidylprolyl isomerase (PPIase) assay

The standard protease-coupled PPIase assay^{12,21} was employed using three peptide substrates having a consensus sequence Suc-Ala-X-Pro-Phe-pNa (Suc, succinyl; X = alanine, lysine or phenylalanine; pNa, paranitroaniline). Assays were performed

by mixing 10 µL of purified rSEQ0694 (60 mg mL⁻¹) or rSEQ0694-parv (40 mg mL⁻¹) (diluted in 20 mM HEPES, pH 7.4; 140 mM NaCl; 10% v/v glycerol), cyclophilin (positive control) or diluent alone (negative control) with 480 µL of buffer (20 mM HEPES, pH 7.4; 140 mM NaCl; 1 mM DTT) and allowing the mixture to equilibrate on ice for 5 min. 10 µL of ice-cold chymotrypsin (20 mg mL⁻¹ in 0.001 M HCl; 0.002 M CaCl₂) was pipetted into a cuvette in a spectrophotometer (Spectronic Unicam Helios-α, Thermos Electron Corporation), zeroed at 390 nm. The 490 µL ice-cold assay mixture was quickly added to and mixed with the chymotrypsin, followed by 500 µL tetrapeptide substrate in ice-cold 20 mM HEPES, pH 7.4, 140 mM NaCl, 1 mM DTT, so as to give a final concentration of 37.5–75 µM peptide, and mixed quickly by pipetting. The final chymotrypsin concentration in the reaction mixture was 0.2 mg mL⁻¹. The rate of the reaction (*cis-trans* isomerization) was measured by following colour formation (absorbance at 390 nm) resulting from pNA release from the *trans* form of the tetrapeptide substrate by chymotrypsin, for a maximum of 6 min. Spectrophotometric readings were recorded automatically *via* Vision 32 (Unicam Ltd) software.

Reported kinetic data are given as the mean value of triplicate measurements for every condition. To ascertain if these data reflected true Michaelis–Menten kinetics, a Lineweaver–Burk plot was constructed and used to determine value of *K_m* (calculated by reciprocalising the X intercept in the Line-weaver-Burk plot). The specificity constant (*M s*) was determined by dividing *K_{cat}* by *K_m*.

Effect of chymotrypsin on rSEQ0694 and rSEQ0694parv recombinant proteins

To determine if chymotrypsin had any significant effect on the recombinant proteins, 10 µL purified rSEQ0694 (60 mg mL⁻¹) or rSEQ0694parv (40 mg mL⁻¹) was incubated with chymotrypsin (10 µL, 20 mg mL⁻¹) in 880 µL assay buffer (20 mM HEPES, pH 7.4; 140 mM NaCl; 1 mM DTT) for 20 s, 2 min and 5 min at 0 °C. The reaction was stopped by the addition of 100 µL 10 mM PMSF and subsequent incubation for 5 min at 0 °C. Incubations containing rSEQ0694 or rSEQ0694parv incubated with PMSF-inactivated chymotrypsin, chymotrypsin with PMSF, chymotrypsin alone, recombinant proteins with PMSF and recombinant proteins alone served as controls. The reactions were analyzed by SDS-PAGE.

Proteomic & bioinformatic methods

To compare protein expression in *S. equi* 4047 and Δ *prtM*_{138–213}, the strains were grown to mid-log phase in Todd Hewitt broth, harvested by centrifugation and total cell proteins prepared as described previously.^{22,23} After removal of cells, supernatant proteins were precipitated with 100% (w/v) trichloroacetic acid, washed three times with ice-cold acetone and processed as for total-cell proteins. Two dimensional electrophoresis (2DE) and protein spot identification following trypsinolysis and mass spectrometry were performed as described previously.^{22,23} Only proteins identified with ≥ 2 peptide matches and Mascot total scores ≥ 50 were included.

Protein sequence alignments were performed using Clustal Omega²⁴ (<http://www.ebi.ac.uk/Tools/msa/clustalo/>).



Physiological tests

Survival of *S. equi* strains in saline solutions was tested by resuspending early stationary phase cells in 0, 0.9%, 14.7% or 29.4% NaCl w/v essentially as described by Reffuveille *et al.*²⁵ Cell suspensions were sampled after 24 and 48 h by serial dilution to 10^{-3} in the same medium and then plated on Todd Hewitt agar plates for enumeration of surviving colony forming units. Antibiotic sensitivity testing was performed by the standard disc diffusion method using discs containing ampicillin (10 μg per disc), penicillin G (6 μg per disc), streptomycin (500 μg per disc), norflaxacin (5 μg per disc) and vancomycin (30 μg per disc). Zones of inhibition were measured after 48 h incubation.

Results and discussion

rSEQ0694 encodes a functional PPIase

Our earlier study of *S. equi* SEQ0694¹⁹ confirmed that this lipoprotein is needed for full virulence but did not directly address its function. Bioinformatic analyses indicated that SEQ0694 exhibits significant pairwise homologies to members of the PrsA/parvulin family of PPIases. In *Firmicutes*, these proteins typically contain a central parvulin domain, flanked by N- and C-terminal domains with likely additional chaperone functions or roles in substrate recruitment,^{13,26,27} although these flanking domains show limited sequence homology (ESI,† Fig. S1). Notably, the parvulin domains of streptococcal and lactococcal PrsA/PrtM family members have been noted to lack key conserved residues^{13,28} (see below) and both *L. lactis* PpmA and *S. pneumoniae* PpmA apparently lack PPIase activity,^{14,29} although it is notable that these proteins can complement some, but not all phenotypes, of a *L. monocytogenes* *prsA2* mutant.³⁰

To confirm *in vitro* PPIase activity of SEQ0694, we produced full-length SEQ0694 as a recombinant protein, rSEQ0694 (ESI,† Fig. S2), for assay using a standard protease-coupled PPIase assay in which the rate of *cis* to *trans* isomerisation of a tetrapeptide substrate is measured through selective and colourigenic chymotrypsin hydrolysis of the *trans* isomer.^{12,21} In addition we produced the central parvulin domain of SEQ0694 as a recombinant protein, rSEQ0694parv. Both recombinant proteins were assayed against three tetrapeptide substrates varying in the amino acid preceding the critical proline residue. Whereas no activity could be detected using tetrapeptide substrates containing lysine–proline or alanine–proline bonds (data not shown), both rSEQ0694 and rSEQ0694parv were found to exhibit PPIase activity using Suc-Ala-Phe-Pro-Phe-pNA as substrate (Fig. 1). However, both recombinant proteins exhibited notably lower activities than the calf thymus cyclophilin used as a positive control.

Recombinant protein stability to chymotrypsin under the assay conditions was assessed. Significant cleavage of rSEQ0694parv by chymotrypsin was observed (ESI,† Fig. S3), whereas rSEQ0694 remained relatively stable for up to 5 min. This meant that although rSEQ0694parv showed an apparently faster rate of reaction compared with rSEQ0694 (Fig. 1), enzyme kinetics could only be determined for the latter (Fig. 2). A $K_{\text{cat}} K_{\text{m}}^{-1}$ of $5.84 \times 10^6/\text{M s}$ for rSEQ0694 was calculated from triplicate




Fig. 1 Protease coupled PPIase assay with (A) 37.5, (B) 50 and (C) 75 μM Suc-Ala-Pro-Phe-pNA peptide substrate. Blue = negative control, red = cyclophilin (positive control), green = rSEQ0694 (full mature protein), purple = rSEQ0694parv (central domain).

PPIase assays, suggesting that rSEQ0694 is a moderately active PPIase compared to other members of the parvulin family, with a similar activity to *E. coli* PpiC (Table 1). This activity was somewhat surprising as sequence alignments indicate that several amino acids considered functionally significant in parvulins^{31–35}






Fig. 2 Kinetic analysis of rSEQ0694. The K_{cat} for rSEQ0694 was determined to be 583.75 s^{-1} and the K_m $100 \mu\text{M}$. Calculated K_{cat}/K_m is $5.84 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$.

are not conserved in rSEQ0694 (Fig. 3). However, a candidate Asp (D187) which might fulfil the role of the critical conserved Asp/Cys could be identified in rSEQ0694 (Fig. 3). Although a role of this Asp/Cys as a catalytic nucleophile is not yet fully resolved,³⁶ its conservation in rSEQ0694 is likely to be significant. Moreover, the conserved residues in bacterial PrsA proteins identified by Jakob *et al.*²⁶ are well conserved in SEQ0694 (ESI,† Fig. S1).

Proteomic analyses to identify putative SEQ0694 substrates

Having established that rSEQ0694 is a *bona fide* PPIase *in vitro*, we were interested to further explore the nature of its substrates. As SEQ0694 is a lipoprotein, we hypothesized that its substrates would be secreted proteins emerging from the Sec translocase, which need to fold rapidly en route to secretion. Misfolded proteins are typically turned over rapidly by extracytoplasmic proteases such as HtrA family members.³⁷ Proteomic approaches have therefore been used to identify extracytoplasmic proteins for which folding is dependent on a lipoprotein PPIase.^{9,12,38,39}

Thus we used proteomics to analyse differential protein expression in the proteomes of *S. equi* 4047 and an isogenic mutant, $\Delta\text{prtM}_{138-213}$, expressing a SEQ0694 N + C domains fusion protein lacking much of the central parvulin domain of SEQ0694¹⁹ (Fig. 3). Note that as the *seq0694* mutant strain was originally designated $\Delta\text{prtM}_{138-213}$ ¹⁹ for consistency we have retained this designation.

Master 2D PAGE gels from 6 matched gel pairs (ESI,† Fig. S4) were analysed for differential protein expression and significant spots identified by mass spectrometry (Tables 2 and 3). Of the detectable total cell proteins, 12 differentially expressed proteins in 10 spots were identified (Table 2). The changes were primarily in cytoplasmic enzymes (*e.g.* enolase) which, because the proteins fold in the cytoplasm, may reflect general responses to stress due to lack of fully functional SEQ0694 (see below). Four of these proteins were also detected in the cell-free supernatant proteins (Table 3). In the cell-free supernatant proteomes, 13 proteins in 17 spots were found to be differentially expressed. As expected, the majority of these are proteins predicted to be either secreted or cell envelope localised and because of this could be plausible substrates for SEQ0694 (Table 3). As multiple proteins were found to be absent from the cell-free supernatant proteome of the mutant strain $\Delta\text{prtM}_{138-213}$, we hypothesise that SEQ0694 is likely to influence folding and secretion of multiple substrates rather than a specific substrate. Interestingly, two previously reported virulence factors of *S. equi* were notably absent from the cell-free supernatant proteome of the $\Delta\text{prtM}_{138-213}$ mutant: the truncated fibronectin-binding protein FNE⁴⁰⁻⁴² and IgG endopeptidase IdeE2.⁴³ FNE is noted to be misannotated as a pseudogene in the strain 4047 genome¹⁷ due to a misplaced start methionine. Our data therefore confirm the expression of FNE by strain 4047. SEQ0882, a putative DNase virulence factor homologous to *S. pyogenes* DNase⁴⁴ was also absent from the cell-free supernatant proteome of the $\Delta\text{prtM}_{138-213}$ mutant.

Cumulatively, these proteomic changes likely explain, at least in part, the attenuation of the $\Delta\text{prtM}_{138-213}$ mutant.¹⁹

Table 1 Comparison of the activities of parvulin family members

Parvulin	Substrate ^a	$K_{cat}/K_m/\text{M s}$	Ref.
rSEQ0694	Phe	5.8×10^6	This study
rSEQ0694	Lys	Inactive	This study
rSEQ0694	Ala	Inactive	This study
<i>B. subtilis</i> PrsA	Lys	1.5×10^4	27 and 33
<i>B. subtilis</i> PrsA	Ala	0.6×10^{4b}	33
<i>B. subtilis</i> PrsA	Glu	0.8×10^{4b}	33
<i>S. aureus</i> PrsA	Lys	0.5×10^{4b}	33
<i>S. aureus</i> PrsA	Ala	1.7×10^{4b}	33
<i>S. aureus</i> PrsA	Glu	3.3×10^4	33
<i>E. coli</i> PpiC (Par10)	Leu	1.3×10^7	46
<i>E. coli</i> PpiC (Par10)	Ser	3.7×10^5	47
<i>E. coli</i> PpiD (Par68)	Ala	1.1×10^{9c}	48
<i>E. coli</i> PpiD (Par68)	Glu	3.4×10^{9c}	48
<i>E. coli</i> PpiD (Par68)	Leu	2.3×10^{9c}	48
Human Pin4 (Par14)	Arg	3.9×10^3	46
<i>L. lactis</i> PpmA	Ala	Inactive ^d	29
<i>S. pneumoniae</i> PpmA	Ala, Phe, Gly, Val, Leu, Gln, Glu	Inactive	14

^a Data from protease-coupled assays where substrate is a colourigenic tetrapeptide Succ-Ala-X-Pro-Phe-pNA in which X is the amino acid indicated in the Table. ^b Estimation from Fig. 1 in Heikkinen *et al.*³³. ^c Subsequently Weininger *et al.*⁴⁹ have reported that PpiD is inactive as a PPIase using modified substrates in a protease-free assay. ^d Data from a protease-free assay using the tetrapeptide Succ-Ala-Ala-Pro-Phe-2,4-difluoroanilide as substrate.



SEQ0694	CQSTND---NTSVITMKGDTISVSDFYNETKNTTEISQRAMLNLVVS RVFEDQYGGKVKSK
Hsa_Par14	-----
Sau_PrsA	CGASATDSKENTLISSKAGDVTVADTMKKIKGDQIA-NASFTEMLNKILADKYKNKVNDK
Eco_PpiC	-----
Bsu_PrsA	CSSGD---KEVIAKTDAGDVTKGELYTNMKTAGASVLTQLVQEKVLDKKY--KVSDK
Lmo_PrsA2	CGG-----GGDVVKTDSDGVTQDELYDAMKDKYGS-EFVQQLTFEKILGDKY--KVSDK
SEQ0694	RTEEAYNKSAEQYG--ASFSAALAQSGLTDDTYKRQIRSAMLVEYAVKEAAKKELTADY
Hsa_Par14	-----MPPKGKSG-----SGKAGKGA-ASGSDSAD
Sau_PrsA	KIDEQIEKMQKQYGGKDKFEKALQQQLTADKYKENLRATAAYHKELLS-DK-IKISDSEI
Eco_PpiC	-----
Bsu_PrsA	EIDNKLKEYKTQLG--DQYTALEKQYG--KDYLKEQVKYELLTQKAAK-DN-IKVTDADI
Lmo_PrsA2	DVDKKFNEYKSQYG--DQFSAVLAQSGLTEKSFKSQKYNLLVQKATE-AN-TDTSDKTL
SEQ0694	KK--AYESYTPEMTTQVTTLDNEET-----AKAVLGEVKAEGADFAAIAK
Hsa_Par14	KKAQGPKGGGNAVVRHILCEKHGK-----IMEA-MEKLKSGMRFNEVAA
Sau_PrsA	KE--D-----SKKASHILIKVKS KSDKEGLDDKEAKQKAEI QKEVSKDPSKFGIEIAK
Eco_PpiC	-----MAKTAALHILVKEEKL-----ALDL-LEQIKNGADFGKLAKE
Bsu_PrsA	KE--YWEGLGKIRASHILVADKKT-----AEEV-EKKLKKGEKFEKDLAK
Lmo_PrsA2	KK--YYETWQPDITVSHILVADENK-----AKEV-EQKLDGAKFADLAK
 : . * :*
SEQ0694	EKTTAADKK--VDYKFDSDGDKLPADV IKAASGLKEGDI SEVSVLDPATYQNKFYIVKV
Hsa_Par14	QYSEDKA--RQGGDLGWMTRGSMVGFQEAALFVSGMDKPVFTDPPVKT KFGYHIIMV
Sau_PrsA	KESMDTGS AKKDGE LGYVLKGQTDKDFEKALFKLK-DGE-----VSEVVKTSFGYHI IKA
Eco_PpiC	KHSICPSGKRGDDLGEFRQGMVPAFDKVVVFCSCPVLE-----PTGPLHTQFGYHI IKV
Bsu_PrsA	EYSTDSSASKGGDLGWFAKEGQMDFTS KAAFLLK-TGE-----VSDPVKTYQYGYHI IKK
Lmo_PrsA2	EYSTD TATKDNGQLAPFGPGKMDPAFEKAAYALKNKGD-----ISAPVKTQYGYHI IQM
	: : . . : : : *
SEQ0694	TKKAEKASDWKKYKRLKEIVLAEKTQN-IDFQNKVIKALDKANVKIKDQAFANILAQY
Hsa_Par14	EGRK-----
Sau_PrsA	DKPT----DFNSEKQSLKEKLVQKVKQKPKLLT DAYKDLLKEYDVDFKDRDIKSVVEDK
Eco_PpiC	LYRN-----
Bsu_PrsA	TEER---GKYDDMKKELKSEVLEQKLNDAAV-QEAVQKVMKKADIEVKDKDLKDTFNST
Lmo_PrsA2	DKPAT-KTTFEKDKKAVKASYLESQ LTT-ENM-QKTLKKEYK DANVKVEDKDLKDAFKDF
SEQ0694	ANTDKKASKANTSKSDQKSSSDSKDSQSSKSKSEK
Hsa_Par14	-----
Sau_PrsA	ILNPEK LKQGG-----QGGQSGMSQ-----
Eco_PpiC	-----
Bsu_PrsA	STS-----NSTSSSSNSK---
Lmo_PrsA2	DGS-----SSSDSDSK-----

Fig. 3 Sequence alignment of SEQ0694 with representative members of the parvulin family. Alignment produced with Clustal Omega. The signal peptide sequences of the *Firmicutes* proteins have been removed so that each sequence starts from the lipidated cysteine at the N-terminus of the mature protein. Key active site residues of the characterised parvulins are highlighted in yellow. For the longer bacterial sequences, the region aligning with the short *E. coli* PpiC sequence corresponds to the central parvulin domain. Realignment of the gapping in the central parvulin domain region in SEQ0694 could bring D187 into alignment with the critical D/C residue present in the characterised parvulins. The position of the region deleted in the *S. equi* mutant strain $\Delta prTM_{138-213}^{19}$ is shown in bold. Abbreviations and UniProt accession codes for the sequences are: Bsu_PrsA (Q81U45); *B. subtilis* PrsA (P24327); Eco_PpiC, *E. coli* PpiC/Par10 (P0A9L5); Hsa_Par14, *Homo sapiens* Pin4 (Q9Y237); LMO_PrsA2, *L. monocytogenes* PrsA2 (Q71XE6); Sau_PrsA, *Staphylococcus aureus* PrsA (A6QI23); and SEQ0694, *S. equi* PrsA (COM9L5).

However, as the $\Delta prTM_{138-213}$ mutant should still express a N + C domain fusion protein (lacking most of the parvulin domain), it may be that more dramatic proteome changes would be evident in an *seq0694* null mutant, since a *L. monocytogenes* PrsA N + C construct partly complemented the proteome defect of a full *prsA* deletion¹² and an N + C fusion construct of *B. subtilis* PrsA

partially restored secretion of an AmyQ reporter protein (although it did not restore viability to PrsA-depleted cells²⁷). In *B. subtilis*, the N and C domain is notable in driving dimerization of PrsA and, although lacking primary sequence homology, has structural similarity to other 'foldases' such as trigger factor.²⁶ Without structural characterisation of the N + C fusion encoded by the



Table 2 Proteins identified in differentially expressed spots on 2DE of cell associated protein extracts of *S. equi* 4047 compared to its isogenic mutant producing an internally deleted SEQ0694

Spot # ^a	Protein identified ^b	Score ^c	Matched peptides ^d	% cover ^e	Predicted function ^f	Signal peptide
WT2201	SEQ0898	1229	17	54	Enolase (PF00113,PF03952)	No
WT2201	SEQ1657	117	3	8	Cyclophilin PPIase (PF00160)	Lipoprotein
WT2201	SEQ0210	91	2	26	10 kDa chaperonin GroES (PF00166)	No
WT3201	SEQ1366	206	5	14	Xaa-His dipeptidase (PF01546)	No
WT3601	SEQ0434	158	3	14	Mannose-6-phosphate isomerase (PF01238)	No
WT4001	SEQ0408	318	6	68	30S ribosomal protein S6 (PF01250)	No
WT4204	SEQ1025	188	3	25	Asp23 domain protein (PF03780)	No
WT5302	SEQ1354	184	3	23	Purine nucleoside phosphorylase (PF01048)	No
WT5504	SEQ0046	293	6	30	Alcohol dehydrogenase (PF00107,PF08240)	No
WT6201	SEQ1418	163	4	26	Putative dTDP-4-keto-6-deoxyglucose-3,5-epimerase (PF00908)	No
WT6501	SEQ1011	408	6	22	6-Phosphofructokinase (PF00365)	No
Prt9401	SEQ1642	103	3	23	Ribosome-recycling factor (PF01765)	No

^a Spot marked in ESI, Fig. S4. WT spots are upregulated or only detected in the wild type strain 4047, Prt spots were only detected in the $\Delta prM_{138-213}$ mutant proteome. ^b As annotated in Holden *et al.*¹⁷ ^c Mascot score. ^d Number of non-redundant peptides identified for each protein. ^e Percent amino acid coverage of entire protein. ^f As determined from Uniprot annotation, BlastP and PFAM analysis.

Table 3 Proteins identified in differentially expressed spots on 2DE of supernatant extracts of *S. equi* 4047 compared to its isogenic mutant producing an internally deleted SEQ0694. WT spots are upregulated or only detected in the wild type strain 4047, Prt spots were only detected in the mutant $\Delta prM_{138-213}$ proteome

Spot # ^a	Protein identified ^b	Score ^c	Matched peptides ^d	% cover ^e	Predicted function ^f	Signal peptide
WT1002	SEQ0210	174	4	57	10 kDa chaperonin GroES (PF00166)	No
WT1401	SEQ1821	334	4	38	PepSY (PF03413) protease inhibitor domain lipoprotein	Lipoprotein
WT1402	SEQ1177	198	5	22	Domain of Unknown Function (PF06207/DUF1002)	Present
WT2101	SEQ1800	119	2	30	Unknown function, no conserved domains. Restricted distribution within streptococci; spot position shifted compared to mutant Prt1103	Present
WT2202	SEQ1025	146	3	20	Asp23 domain protein (PF03780)	No
WT2202	FNE	72	2	6	Truncated fibronectin binding protein (PF08341)	Present
WT2401	SEQ1177	526	8	36	Domain of unknown function (PF06207/DUF1002)	Present
WT3301	SEQ1657	409	6	35	Cyclophilin type PPIase (PF00160)	Lipoprotein
WT7301	SEQ0882	519	7	39	DNA/RNA non-specific endonuclease	Present
WT7301	FNE	361	6	26	Truncated fibronectin binding protein (PF08341)	Present
WT8401	SEQ0938	331	6	19	IdeE2 Mac family protein (PF09028)	Present
WT8501	SEQ0938	204	4	11	IdeE2 Mac family protein (PF09028)	Present
WT9202	FNE	221	5	13	Truncated fibronectin binding protein (PF08341)	Present
WT9202	SEQ0882	93	3	14	DNA/RNA non-specific endonuclease	Present
WT9403	SEQ0520	556	10	41	Hydrolase/esterase (PF07859)	Present
Prt0301	SEQ1171	165	4	25	Sortase A (PF04203)	Signal anchor
Prt1103	SEQ1800	133	3	36	Unknown function, no conserved domains. Restricted distribution within streptococci; position shifted compared to mutant WT2101.	Present
Prt1202	SEQ1919	221	3	6	OppA oligopeptide binding lipoprotein (PF00496)	Lipoprotein
Prt2101	SEQ0408	139	2	26	30S ribosomal protein S6 (PF01250)	No
Prt2301	SEQ1919	86	3	6	OppA oligopeptide binding lipoprotein (PF00496)	Lipoprotein

^a Spot marked in ESI, Fig. S4. ^b As annotated in Holden *et al.*¹⁷ ^c Mascot score. ^d Number of non-redundant peptides identified for each protein. ^e Percent amino acid coverage of entire protein. ^f As determined from Uniprot annotation, BlastP and PFAM analysis.

S. equi $\Delta prM_{138-213}$ mutant we cannot speculate whether this construct is likely to have a native-like conformation and functionality. However, it is notable that the sequence deletion removes not only the majority of the parvulin domain of SEQ0694 but also a conserved lysine of the *Firmicutes* PrsA protein N-domains. It is worth reemphasising that the partial deletion in the *S. equi* $\Delta prM_{138-213}$ mutant is sufficient to cause significant attenuation of virulence in the natural host.¹⁹

It was interesting to note that SEQ1657, a cyclophilin PPIase lipoprotein (orthologous to *S. pneumoniae* SlrA¹⁴ and *L. lactis* PpiA²⁹) was up-regulated in both the total cell and secreted proteins of the parental strain. Likewise, it was observed that

the SEQ1171 sortase is up-regulated in the mutant strain, perhaps suggesting a need to remodel protein localisation within the mutant cell envelope.

As the proteomic data suggested a range of protein functions are likely to be perturbed in strain $\Delta prM_{138-213}$, including stress responses, we performed several physiological tests. Although the mutant strain grows normally in nutrient rich broth, we observed pleiotropic changes including increased sensitivity to salt stress (ESI,† Table S1) and increased sensitivity to various antibiotics with diverse cellular targets (ESI,† Fig. S5). Increased sensitivity to salt stress has previously been observed in a *prsA* mutant of *E. faecalis*¹¹ and a *prsA2* mutant



of *L. monocytogenes*.³⁰ A range of findings have been observed regarding antibiotic susceptibilities of other *prsA* mutants. Similar to our findings, a *prsA2* mutant of *L. monocytogenes* displayed increased sensitivity to bacitracin, penicillin and vancomycin but not gentamicin³⁰ and a mutant in *Staphylococcus aureus prsA* showed increased sensitivity to vancomycin.⁴⁵ However, a *prsA* mutant of *E. faecalis* was unaffected in its sensitivity to ampicillin and norflaxin,¹¹ in contrast to our findings. Cumulatively, our data suggest a general perturbation in cell envelope function in the $\Delta prtM_{138-213}$ mutant, which likely reflects multiple changes in the extracytoplasmic proteome of the mutant (consistent with our proteomic data). This conclusion is consistent with the pleiotropic effects of *PrsA* mutation in other *Firmicutes*.^{11,28,30,45}

Conclusions

The data presented here confirm that rSEQ0694 is a moderately active PPIase, despite lacking conservation of several amino acids previously considered to be significant to the activity of other parvulin PPIases. This observation thus focusses attention on the conserved Asp/Cys identified as likely critical for catalysis. Furthermore, proteomic experiments confirm that loss of the lipoprotein PPIase activity in strain $\Delta prtM_{138-213}$ affects multiple cell envelope proteins, including virulence factors, and is likely to generate diverse phenotypic effects. As strain $\Delta prtM_{138-213}$ is attenuated,¹⁹ these findings further suggest that streptococcal PPIases, and PPIases generally,⁷ are interesting targets for novel therapeutic strategies. By analogy with other bacterial PPIases, it would also be of interest to determine whether the N- and C-terminal domains of SEQ0694 possess additional chaperone activities that contribute to post-translocational protein folding.

Abbreviations

<i>pNa</i>	Paranitroaniline
PPIase	Peptidyl-prolyl isomerase
rSEQ0694	Recombinant N-terminally His-tagged mature SEQ0694
rSEQ0694parv	Recombinant N-terminally His-tagged parvulin domain of SEQ0694

References

- R. E. Dalbey and A. Kuhn, *FEMS Microbiol. Rev.*, 2012, **36**, 1023–1045.
- M. Desvaux, M. Hébraud, R. Talon and I. R. Henderson, *Trends Microbiol.*, 2009, **17**, 139–145.
- R. Freudl, *Res. Microbiol.*, 2013, **164**, 664–674.
- C. Goemans, K. Denoncin and J. F. Collet, *Biochim. Biophys. Acta*, 2014, **1843**, 1517–1528.
- M. Sarvas, C. R. Harwood, S. Bron and J. M. van Dijl, *Biochim. Biophys. Acta*, 2004, **1694**, 311–327.
- J. Fanghänel and G. Fischer, *Front. Biosci.*, 2004, **9**, 3453–3478.
- C. M. Únala and M. Steinert, *Microbiol. Mol. Biol. Rev.*, 2014, **78**, 544–571.
- M. I. Hutchings, T. Palmer, D. J. Harrington and I. C. Sutcliffe, *Trends Microbiol.*, 2009, **17**, 13–21.
- H. L. Hyryläinen, B. C. Marciniak, K. Dahncke, M. Pietiäinen, P. Courtin, M. Vitikainen, R. Seppala, A. Otto, D. Becher, M. P. Chapot-Chartier, O. P. Kuipers and V. P. Kontinen, *Mol. Microbiol.*, 2010, **77**, 108–127.
- R. C. Williams, M. L. Rees, M. F. Jacobs, Z. Pragai, J. E. Thwaite, L. W. Baillie, P. T. Emmerson and C. R. Harwood, *J. Biol. Chem.*, 2003, **278**, 18056–18062.
- F. Reffuveille, N. Connil, M. Sanguinetti, B. Posteraro, S. Chevalier, Y. Auffray and A. Rince, *Infect. Immun.*, 2012, **80**, 1728–1735.
- F. Alonzo, 3rd, B. Xayarath, J. C. Whisstock and N. E. Freitag, *Mol. Microbiol.*, 2011, **80**, 1530–1548.
- L. A. Cahoon and N. E. Freitag, *Front. Cell. Infect. Microbiol.*, 2014, **4**, 13.
- P. W. Hermans, P. V. Adrian, C. Albert, S. Estevo, T. Hoogenboezem, I. H. Luijendijk, T. Kamphausen and S. Hammerschmidt, *J. Biol. Chem.*, 2006, **281**, 968–976.
- Y. Ma, A. E. Bryant, D. B. Salmi, S. M. Hayes-Schroer, E. McIndoo, M. J. Aldape and D. L. Stevens, *J. Bacteriol.*, 2006, **188**, 7626–7634.
- J. U. Rahfeld, K. P. Rücknagel, B. Schelbert, B. Ludwig, J. Hacker, K. Mann and G. Fischer, *FEBS Lett.*, 1994, **352**, 180–184.
- M. T. Holden, Z. Heather, R. Paillot, K. F. Steward, K. Webb, F. Ainslie, T. Jourdan, N. C. Bason, N. E. Holroyd, K. Mungall, M. A. Quail, M. Sanders, M. Simmonds, D. Willey, K. Brooks, D. M. Aanensen, B. G. Spratt, K. A. Jolley, M. C. Maiden, M. Kehoe, N. Chanter, S. D. Bentley, C. Robinson, D. J. Maskell, J. Parkhill and A. S. Waller, *PLoS Pathog.*, 2009, **5**, e1000346.
- A. S. Waller, R. Paillot and J. F. Timoney, *J. Med. Microbiol.*, 2011, **60**, 1231–1240.
- A. Hamilton, C. Robinson, I. C. Sutcliffe, J. Slater, D. J. Maskell, N. Davis-Poynter, K. Smith, A. Waller and D. J. Harrington, *Infect. Immun.*, 2006, **74**, 6907–6919.
- V. Malik, M. Zhang, L. G. Dover, J. S. Northen, A. Flinn, J. J. Perry and G. W. Black, *Mol. Biosyst.*, 2013, **9**, 2816–2822.
- J. Hani, B. Schelbert, A. Bernhardt, H. Domdey, G. Fischer, K. Wiebauer and J. U. Rahfeld, *J. Biol. Chem.*, 1999, **274**, 108–116.
- Q. Yang, M. Zhang, D. J. Harrington, G. W. Black and I. C. Sutcliffe, *Int. J. Med. Microbiol.*, 2010, **300**, 331–337.
- M. Zhang, F. M. McDonald, S. S. Sturrock, S. J. Charnock, I. Humphery-Smith and G. W. Black, *Proteomics*, 2007, **7**, 1379–1390.
- F. Sievers, A. Wilm, D. Dineen, T. J. Gibson, K. Karplus, W. Li, R. Lopez, H. McWilliam, M. Remmert, J. Soding, J. D. Thompson and D. G. Higgins, *Mol. Syst. Biol.*, 2011, **7**, 539.
- F. Reffuveille, P. Serror, S. Chevalier, A. Budin-Verneuil, R. Ladjouzi, B. Bernay, Y. Auffray and A. Rince, *Microbiology*, 2012, **158**, 816–825.
- R. P. Jakob, J. R. Koch, B. M. Burmann, P. A. Schmidpeter, M. Hunkeler, S. Hiller, F. X. Schmid and T. Maier, *J. Biol. Chem.*, 2015, **290**, 3278–3292.



- 27 M. Vitikainen, I. Lappalainen, R. Seppala, H. Antelmann, H. Boer, S. Taira, H. Savilahti, M. Hecker, M. Vihinen, M. Sarvas and V. P. Kontinen, *J. Biol. Chem.*, 2004, **279**, 19302–19314.
- 28 S. Drouault, J. Anba, S. Bonneau, A. Bolotin, S. D. Ehrlich and P. Renault, *Appl. Environ. Microbiol.*, 2002, **68**, 3932–3942.
- 29 N. Trémillon, E. Morello, D. Llull, R. Mazmouz, J. J. Gratadoux, A. Guillot, M. P. Chapot-Chartier, L. Monlezun, V. Solé, H. Ginisty and I. Poquet, *PLoS One*, 2012, **7**, e33516.
- 30 L. A. Cahoon and N. E. Freitag, *Infect. Immun.*, 2015, **83**, 4028–4041.
- 31 M. L. Bailey, B. H. Shilton, C. J. Brandl and D. W. Litchfield, *Biochemistry*, 2008, **47**, 11481–11489.
- 32 C. D. Behrsin, M. L. Bailey, K. S. Bateman, K. S. Hamilton, L. M. Wahl, C. J. Brandl, B. H. Shilton and D. W. Litchfield, *J. Mol. Biol.*, 2007, **365**, 1143–1162.
- 33 O. Heikkinen, R. Seppala, H. Tossavainen, S. Heikkinen, H. Koskela, P. Permi and I. Kilpeläinen, *BMC Struct. Biol.*, 2009, **9**, 17.
- 34 J. W. Mueller, N. M. Link, A. Matena, L. Hoppstock, A. Rüppel, P. Bayer and W. Blankenfeldt, *J. Am. Chem. Soc.*, 2011, **133**, 20096–20099.
- 35 H. Tossavainen, P. Permi, S. L. Purhonen, M. Sarvas, I. Kilpeläinen and R. Seppala, *FEBS Lett.*, 2006, **580**, 1822–1826.
- 36 A. Barman and D. Hamelberg, *Biochemistry*, 2014, **53**, 3839–3850.
- 37 G. Hansen and R. Hilgenfeld, *Cell. Mol. Life Sci.*, 2013, **70**, 761–775.
- 38 F. Alonzo, 3rd and N. E. Freitag, *Infect. Immun.*, 2010, **78**, 4944–4957.
- 39 L. Guo, T. Wu, W. Hu, X. He, S. Sharma, P. Webster, J. K. Gimzewski, X. Zhou, R. Lux and W. Shi, *Mol. Oral Microbiol.*, 2013, **28**, 154–165.
- 40 A. Lidén, A. Karlstrom, J. Lannergård, S. Kalamajski, B. Guss, K. Rubin and C. Rydén, *Biochem. Biophys. Res. Commun.*, 2006, **340**, 604–610.
- 41 H. Lindmark, M. Nilsson and B. Guss, *Infect. Immun.*, 2001, **69**, 3159–3163.
- 42 M. Tiouajni, D. Durand, K. Blondeau, M. Graille, A. Urvoas, M. Valerio-Lepiniec, A. Guellouz, M. Aumont-Nicaise, P. Minard and H. van Tilbeurgh, *FEBS J.*, 2014, **281**, 5513–5531.
- 43 G. Hulting, M. Flock, L. Frykberg, J. Lannergård, J. I. Flock and B. Guss, *FEMS Microbiol. Lett.*, 2009, **298**, 44–50.
- 44 J. E. Korczynska, J. P. Turkenburg and E. J. Taylor, *Nucleic Acids Res.*, 2012, **40**, 928–938.
- 45 A. Jouselin, A. Renzoni, D. O. Andrey, A. Monod, D. P. Lew and W. L. Kelley, *Antimicrob. Agents Chemother.*, 2012, **56**, 3629–3640.
- 46 T. Uchida, F. Fujimori, T. Tradler, G. Fischer and J. U. Rahfeld, *FEBS Lett.*, 1999, **446**, 278–282.
- 47 R. Golbik, C. Yu, E. Weyher-Stingl, R. Huber, L. Moroder, N. Budisa and C. Schiene-Fischer, *Biochemistry*, 2005, **44**, 16026–16034.
- 48 C. Dartigalongue and S. Raina, *EMBO J.*, 1998, **17**, 3968–3980.
- 49 U. Weininger, R. P. Jakob, M. Kovermann, J. Balbach and F. X. Schmid, *Protein Sci.*, 2010, **19**, 6–18.

